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ABSTRACT 1 
Background: 2 
Prophylactic central neck dissection (pCND) at the time of total thyroidectomy (TT) remains 3 
controversial in clinically node- negative (cN0) papillary thyroid carcinoma (PTC). Despite 4 
occult central lymph node metastases being common, it is unclear if removing these metastases 5 
initially would reduce future locoregional recurrence (LRR). This systematic review and meta-6 
analysis aimed at comparing the short-term LRR between patients who underwent TT+pCND 7 
and TT alone. 8 
Methods: 9 
A systematic review of the literature was performed to identify studies comparing LRR between 10 
patients with PTC who underwent TT+pCND (group A) and TT alone (group B). Inclusion 11 
criteria were: patients had to have cN0, each comparative group contained > 10 patients, the 12 
number of LRR and mean follow-up duration had to be available. The pooled incidence rate ratio 13 
(IRR) was used for calculating the LRR rate between the two groups. Other parameters evaluated 14 
included postoperative radioiodine (RAI) ablation, surgically-related complications and overall 15 
morbidity. Meta-analysis was performed using a fixed-effects model. 16 
Results: 17 
Fourteen studies matched the selection criteria. Of the 3331 patients, 1592 (47.8%) belonged to 18 
group A while 1739 (52.2%) to group B. Relative to group B, group A was significantly more 19 
likely to have postoperative RAI ablation (71.7% vs. 53.1%;OR=2.60; 95%CI=2.12 – 3.18), 20 
temporary hypocalcemia (26.0% vs. 10.8%;OR=2.56; 95%CI=2.04 – 3.21) and overall morbidity 21 
(33.2% vs. 17.7%;OR=2.12; 95%=1.75 – 2.57). When temporary hypocalcemia was excluded, 22 
overall morbidity became similar between the two groups (7.3% vs. 6.8%; 23 
OR=1.07;95%CI=0.78 – 1.47). Group A had significantly lower risk of LRR than group B (4.7% 24 
vs. 8.6%;IRR=0.65; 95%CI=0.48 – 0.86) 25 
Conclusions: 26 
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Group A was more likely to have postoperative RAI ablation, temporary hypocalcemia and 1 
overall morbidity than B. Temporary hypocalcemia was the major surgical morbidity in pCND 2 
and when excluded, the overall morbidity appeared similar between the two groups. Although 3 
our meta-analysis would suggest that those who undergo TT+pCND may have a 35% reduction 4 
in risk of LRR than those who undergo TT alone in the short term (<5 years), it remains unclear 5 
how much of this risk reduction is related to increased use of RAI ablation and potential 6 
selection bias in some of the studies examined. 7 
8 
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INTRODUCTION 1 
Papillary thyroid carcinoma (PTC) is the most common type of differentiated thyroid carcinoma 2 
with its age-adjusted incidence doubled in the last 25 years (1). Despite its good prognosis, 3 
locoregional recurrence (LRR) is common (2). With recognition of the step-wise progression of 4 
lymph node metastasis (LNM) from the central (level VI) to lateral compartment (levels II-V), 5 
some surgeons have advocated routine prophylactic central neck dissection (pCND) at the time 6 
of total thyroidectomy for PTC (3). Although there is general agreement that formal lymph node 7 
dissection should be performed in the setting of imageable, biopsy-proven or palpable nodal 8 
disease (cN1), it remains controversial in patients with no clinical evidence of nodal metastasis 9 
(cN0) (4). There is little evidence to suggest that patients with cN0 undergoing a total 10 
thyroidectomy (TT) and pCND (TT+pCND) would reduce risk of future LRR when compared to 11 
TT alone. Although the incidence of occult or microscopic LNM in patients with cN0 is 12 
relatively common, it is unclear whether removing these occult or microscopic LNM at the time 13 
of primary operation could prevent LRR (5,6). Analysis of short-term surrogates for recurrence 14 
(such as post-surgical thyroglobulin level) would suggest that pCND may improve short-term 15 
outcomes but this has not been fully resolved (4,7,8). Furthermore, patients undergoing pCND 16 
are at increased risk of temporary hypocalcemia (9-11).  17 
One of the main reasons for the lack of evidence is that studies so far comparing TT+pCND and 18 
TT alone have not had the statistical power to detect a difference of LRR. A recent study 19 
estimated over 5000 patients would be required to have sufficient statistical power to 20 
demonstrate a 25% reduction in LRR with pCND in patients with cN0 (12). To our knowledge, 3 21 
meta-analyses have compared the outcomes between TT+pCND and TT alone. Two were not 22 
strictly relevant because one included patients with benign disease while the other included 23 
patients who underwent therapeutic CND (9,10). Zetoune et al. pooled together 5 relevant studies 24 
and found similar overall LRR rate between TT+pCND and TT alone (2.02% vs. 25 
3.92%;OR=1.05;95%CI=0.44 – 3.91) (11). However, this study did not account for the 26 
difference in follow-up duration between the two groups. With an increasing number of new 27 
publications on this controversial subject in recent years, we conducted a systematic review and 28 
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meta-analysis to compare the risk of LRR between TT+pCND and TT alone by reviewing the 1 
current literature. 2 
3 
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METHODS 1 
This systematic review and meta-analysis was conducted in accordance with the PRISMA 2 
statement (13). 3 
Search strategy 4 
Studies comparing the rate of LRR between patients who underwent TT+pCND and TT alone 5 
were retrieved from the Scopus, Medline (PubMed) and Cochrane Library electronic databases 6 
on 30th January 2013. We used the following free text search terms in “All fields” 7 
#1: ‘central neck dissection’ OR ‘level VI neck dissection’ OR ‘neck dissection’ 8 
#2: ‘papillary thyroid carcinoma’ 9 
#3: #1 AND #2  10 
There was no language restriction or methodological filters. The bibliographies of three previous 11 
meta-analyses were searched for other additional relevant references (9-11). 12 
Study selection 13 
All titles identified by the search strategy were independently screened by three authors (BHL, 14 
SHN, KPW). Search results were compared, and disagreements were resolved by consensus. 15 
Abstracts of potentially relevant titles were then reviewed for eligibility and full-length articles 16 
were selected for closer examination if there was a specific description on central neck dissection 17 
in patients with papillary thyroid carcinoma. The criteria for eligibility were: 1. any prospective 18 
or retrospective studies on patients with papillary thyroid carcinoma only; studies which 19 
analyzed differentiated thyroid carcinoma were considered if results of PTC were separately 20 
reported; 2. studies with two arms comparing LRR between TT+pCND and TT alone; 3. each 21 
study arm had to have > 10 patients; 4. patients in either arm had to be cN0 by preoperative 22 
imaging and intraoperative examination; patients with cN1 or distant metastasis (M1) were not 23 
included; 5. The number of LRR and the mean follow-up (in months) in each study arm had to 24 
be available. The reason for obtaining the mean follow-up period was because in order to work 25 
out the pooled incidence rate ratio (IRR) for TT+pCND and TT alone groups, we had to have 26 
first calculate the number of person-years in each respective arm. Studies which specifically 27 
reported the number of LRR and follow-up period in TT+pCND and TT alone as subgroups were 28 
included. Patients who underwent hemithyroidectomy with pCND or underwent simultaneous 29 
pCND and prophylactic lateral neck dissection were excluded. For studies which only provided 30 
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the number of LRR without the mean follow-up duration or provided only the median and not 1 
the mean follow-up duration, the corresponding author of those studies was individually 2 
contacted for further information. Multiple reports of the same dataset were assessed and the 3 
most updated report of a study was included.  4 
Data extraction 5 
All data were extracted onto a standardized form. The primary data extracted from each article 6 
included: type or design of study, first authorship, country of origin, year of publication, patient 7 
demographics, preoperative nodal assessment, method of selection for pCND, tumor 8 
characteristics, number of patients who underwent TT+pCND or TT alone, extent of pCND 9 
(unilateral vs. bilateral), number of normal and metastatic central LNs harvested, mean follow-up 10 
period, radioiodine (RAI) ablation given or not, number of LRR, operating time, volume of 11 
blood loss and any surgically-related morbidities. LRR was defined as a recurrence occurring in 12 
the thyroid bed, central and / or lateral compartments. A patient found to have distant recurrence 13 
only (i.e. without concomitant LRR) was not counted as a LRR while a patient with concomitant 14 
LRR and distant recurrence was counted as a LRR. The percentage of recurrent laryngeal nerve 15 
(RLN) injury was calculated based on the number of patients. The overall morbidity rate was 16 
calculated by dividing the total number of patients who suffered ≥ 1 perioperative morbidity over 17 
the total number of patients. If a patient suffered from ≥ 2 morbidities, it was counted as one. 18 
Statistical analysis 19 
All the individual outcomes were integrated with the meta-analysis software Review Manager 20 
Software 5.0 (Cochrane Collaborative, Oxford, England). LRR was assessed by IRR according 21 
to person-year of follow up, and odds ratios (OR) were examined for the other surgical outcomes. 22 
All results were aggregated and analyzed using a fixed-effects model. A subgroup analysis of 23 
overall morbidity was performed excluding temporary postoperative hypocalcemia. Publication 24 
bias was estimated by Begg’s rank correlation test and Egger’s regression test (14,15). The meta-25 
analyses in this study were conducted using R version 2.15.1 (R Foundation for Statistical 26 
Computing, Vienna, Austria) and the metafor package (16). 27 
 28 
29 
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RESULTS 1 
Figure 1 shows the flowchart of studies retrieved and excluded. Of the 1822 titles initially 2 
identified from the database search, 41 full-length articles were assessed for inclusion, of which 3 
27 were excluded and 14 studies were determined to be eligible and were included in this 4 
systematic review (7,17-29). Table 1 lists these 27 articles and the reason for their exclusion. No 5 
additional study was found from our search of the three bibliographies in previous meta-analyses 6 
(9-11). One study (8) was excluded as it analyzed a subset of study subjects that were later 7 
recruited in a multi-center cohort study (25). 8 
Baseline characteristics 9 
Table 2 shows a comparison of the baseline characteristics between the 14 eligible studies. There 10 
was no randomized trial. Thirteen studies were retrospective while one was prospective. Of the 11 
3331 patients included, 1592 (47.8%) had TT + pCND (group A) while 1739 (52.2%) had TT 12 
only (group B). In terms of preoperative nodal assessment, ultrasonography (USG) was used as 13 
the standard imaging modality in all studies but only 2 studies specifically mentioned both 14 
bilateral central and lateral neck compartments were examined (25,27). 15 
In terms of selection for pCND, 7 studies were based on individual surgeon’s preference 16 
(7,18,22,24,25,27,28) while 4 studies did not specify their method of selection (17,19,23,26). 17 
Three studies used historical controls (TT alone) for comparison (20,21,29). Only 11 of 14 18 
studies statistically compared age, gender ratio, tumor size, extrathyroidal extension and tumor 19 
multifocality between the two groups (7,17,18,21-26,28,29). Of these, 2 studies found age to be 20 
significantly older in group B (21,25) and 3 studies found tumor size to be significantly different 21 
(7,21,23). Two studies found tumor size to be significantly larger in group A (7,21) while one 22 
study found tumor size to be significantly smaller in group A (23). Three of 9 studies found the 23 
rate of extrathyroidal extension to be significantly higher in group A (7,22,24) and 2 of 9 studies 24 
found the rate of tumor multifocality to be significantly higher in group A (22,26). Bilateral 25 
pCND was performed in 8 studies (17,18,22-24,26,28,29) while the other 6 studies performed 26 
either unilateral or a combination of unilateral and bilateral pCND (7,19,20,21,25,27). Among 27 
the 8 studies reporting bilateral pCND,(17,18,22-24,26,28,29) the mean number of central lymph 28 
nodes harvested ranged between 5.6 to 9.6 while the one study reporting unilateral pCND 29 
harvested a median of 5 (7). The incidence of central LNM in group A ranged from 23.5% to 30 
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82.4% while in group B, it ranged from 0.9% to 9.7% with 9 of 14 studies did not report the 1 
incidence of central LNM in group B. 2 
Surgical outcomes 3 
Table 3 shows a comparison of outcomes between the two groups. Only 9 of the 14 studies 4 
reported whether RAI ablation was given after surgery (7,18,21-24,26,27,29). Their dose ranged 5 
from 2.78 to 5.55 GBq. One study empirically gave the same dose of RAI, irrespective of the 6 
extent of LNM (7). The mean frequency of postoperative RAI ablation in group A and B were 7 
746/1041 (71.7%) and 498/937 (53.1%). Group A was significantly more likely to receive RAI 8 
ablation than group B (OR=2.60; 95%CI=2.12 – 3.18). This was expected because of the higher 9 
incidence of central LNM (or N1a) in group A leading to tumor group upstaging in patients aged 10 
> 45 years old (28). Only 1 of 14 studies compared operating time between the two groups and 11 
found group B to have a significantly shorter operating time than group A (28). 12 
Figure 2 shows the forest plot for temporary hypocalcemia. Of the 14 studies, 11 studies 13 
compared temporary postoperative hypocalcemia between the two groups while 10 studies 14 
compared permanent postoperative hypocalcemia in the two groups. In 8 studies, permanent 15 
hypocalcemia was defined as persistent hypocalcemia and/or need for calcium supplements > 6 16 
months (7,20,23-27,28) while two studies defined it as hypocalcemia > 12 months (18,29). If one 17 
assumed all studies utilized a similar definition for temporary and permanent hypocalcemia, the 18 
overall temporary hypocalcaemia rate in group A was significantly higher than that in B 19 
(336/1294 (26.0%) and 144/1330 (10.8%) respectively; OR=2.56, 95%CI= 2.04 – 3.21) while 20 
the overall permanent hypocalcaemia was also similar between the group A and B (25/1254 21 
(2.0%) and 15/1257 (1.2%), respectively; OR=1.74, 95%CI= 0.87 – 3.50). 22 
Similar to hypocalcemia, the definition for temporary and permanent RLN injury varied between 23 
studies. Routine perioperative DL was performed in 5 studies (7,25,26,28,29) and persistent 24 
impairment in vocal cord function > 6-month was defined as permanent RLN injury in 7 studies 25 
(19,23-27). The cumulative temporary RLN palsy was comparable between group A and B 26 
(42/1294 (3.2%) and 41/1330 (3.1%) respectively) (OR=1.02; 95%CI= 0.64 – 1.64). The 27 
cumulative permanent RLN palsy was also comparable between the group A and B (14/1197 28 
(1.2%) and 21/1240 (1.7%), respectively) (OR=0.75; 95%CI= 0.37 – 1.55). 29 
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The rate of hematoma was reported in 8 studies. The cumulative hematoma rate was comparable 1 
between group A and B (8/842 (1.0%) and 7/975 (0.9%), respectively) (OR=1.33; 95%CI= 2 
0.53 – 3.35). The wound infection / seroma rate was also similar between group A and B (3/842 3 
(0.4%) and 7/975 (0.9%), respectively) (OR=0.78; 95%CI=0.28 – 2.07). Figure 3 shows the 4 
forest plot for overall morbidity. The overall morbidity rate ranged between 14.3% to 53.8% in 5 
group A while in group B, it ranged between 11.0% to 40.7%. The overall morbidity after 6 
thyroid surgery in group A was significantly higher than group B (430/1294 (33.2%) vs. 7 
235/1330 (17.7%); OR=2.12, 95%CI=1.75 – 2.57). However, after excluding temporary 8 
hypocalcemia, the overall morbidity in group A was not significantly different from group B 9 
(94/1294 (7.3%) vs. 90/1330 (6.8%); OR=1.07; 95%CI=0.78 – 1.47). Figure 4 shows the forest 10 
plot for overall morbidity after excluding temporary hypocalcemia. The potential publication 11 
bias did not appear significant, as confirmed by the Begg analysis (Kendall’s tau = -0.1636, 12 
p=0.5423) and the Egger regression test (z= -0.8921, p=0.4167). 13 
LRR 14 
Table 4 compares the LRR rate between the two groups. One study was excluded in the IRR 15 
calculation because the mean duration of follow-up was not available (19). Figure 5 shows the 16 
forest plot for LRR. The pooled mean follow-up in group A and B were 45.2 and 50.8 months, 17 
respectively while the pooled mean number of person-years in group A and B were 598.9 and 18 
662.3, respectively. Group A had significantly lower LRR than group B (75/1592 (4.7%) vs. 19 
149/1739 (8.6%); IRR=0.65; 95%CI=0.48 – 0.86). The potential publication bias was not 20 
significant, as confirmed by Begg analysis (Kendall’s tau = -0.1677, p=0.4268) and the Egger 21 
regression test (z= 0.0984, p=0.9216). 22 
 23 
24 
12 
 
DISCUSSION 1 
To our knowledge, this is to date one the largest meta-analyses evaluating the impact of pCND 2 
on LRR in patients with clinically-nodal negative PTC or cN0. With significantly more patients 3 
being included than previous meta-analyses, our data suggested that those who undergo 4 
TT+pCND have a 35% reduction in risk of LRR than those who undergo TT alone. Although no 5 
significant publication bias was found in our meta-analysis as shown by the Begg’s rank 6 
correlation test and Egger’s regression test, it is worth nothing there was one particular large 7 
recent study which could have had a profound impact on the overall IRR (29). In fact, its number 8 
of person-years in group A and B were almost 2-3 times of that of the next largest study (25). 9 
Nevertheless, on the funnel plot (data not shown), this particular study was just on the margin of 10 
the funnel and therefore, it was not excluded from the final meta-analysis. 11 
Despite this important positive finding, we remained cautious as there were a number of 12 
potential problems identified. Firstly, the mean follow-up period was relatively short with one 13 
study having a mean follow-up period of only 10 months. In fact, the overall mean follow-up 14 
duration for group A and B was only 45.2 and 50.8 months, respectively and so both groups had 15 
a mean follow-up of less than 5 years. Given the fact that PTC is a relatively slow-growing, 16 
indolent tumor, patients may not develop detectable LRR until many years after the initial 17 
operation. Therefore, a significant longer follow-up duration would be necessary to fully assess 18 
whether pCND could significantly reduce LRR at least in the medium to long term (12). Apart 19 
from this, 13 of 14 studies were retrospective analyses and so they were subjected to selection 20 
bias. Surgeon’s preference or discretion was mentioned in 7 of 14 studies as their method of 21 
selecting pCND while 4 studies did not clearly describe their method of selection. Three studies 22 
actually used historical controls for outcome comparison (20,21,29). These selection biases were 23 
evident by the fact that only 1 of the 5 baseline characteristics (i.e. gender ratio) was consistently 24 
comparable in all studies. The other baseline characteristics such as age, tumor size, presence of 25 
extrathyroidal extension and tumor multifocality were not consistently comparable and since 26 
some of these could also potentially influence the risk of LRR, it was difficult to assess the real 27 
impact of pCND on LRR. Accounting for these factors in the multivariate analysis may help but 28 
not all these characteristics were readily available for analysis. Perhaps, the best way to resolve 29 
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this would be to conduct a prospective randomized trial in the future. Although all studies did 1 
mention using USG as a method for preoperative nodal assessment, it was difficult to assess the 2 
quality and the comprehensiveness of the assessment. This issue was particularly relevant in the 3 
three studies where historical controls were analyzed because quality of imaging tended to 4 
change with time. Furthermore, it was unclear from these studies what USG criteria were used 5 
for deciding on fine needle aspiration or surgery.  6 
In terms of other outcomes, similar to previous studies,(7,24,27) we found the rate of 7 
postoperative RAI ablation was significantly higher in group A than B (71.7% vs. 53.1%, 8 
respectively; OR=2.60; 95%CI=2.12 – 3.18). This was likely attributed to the higher incidence of 9 
central LNM in group A relative to B. However, it was interesting to note the incidence of 10 
central LNM varied widely from 23.5% to 82.4% between studies. Perhaps, this was also a 11 
reflection of the quality of preoperative USG assessment and might also have been a result of 12 
differences in the extent of the pCND and quality of the histological examination between 13 
studies (5,30,31). Also similar to previous meta-analyses,(9-11) we found the temporary 14 
hypocalcemia to be significantly higher in group A than B (26.0% vs. 10.8%, respectively; 15 
OR=2.56;95%CI=2.04 – 3.21). This would suggest that patients undergoing pCND during TT 16 
are at 2.6 times more likely to develop temporary hypocalcemia than TT alone. This was 17 
undoubtedly related to increased extent of surgical dissection leading to devascularization of 18 
parathyroid glands and / or inadvertent removal of parathyroid glands (7,17-27). However, it is 19 
worth noting that the rate of permanent hypocalcemia, temporary and permanent RLN injury, 20 
hematoma and wound infection/seroma were not dissimilar between the two groups. Also even 21 
though the overall morbidity was significantly higher in group A than B 22 
(OR=2.12;95%CI=1.75 – 2.57), when this analysis was repeated with temporary hypocalcemia 23 
excluded, the overall morbidity was similar between group A and B (OR=1.07;95%CI=0.78 – 24 
1.47). This finding implied that the majority of morbidity arising from pCND was actually 25 
related to temporary hypocalcemia rather than other surgically-related complications. 26 
Conclusion 27 
The addition of pCND in TT resulted in greater likelihood of administrating postoperative RAI 28 
ablation, temporary hypocalcemia and overall morbidity. However, since temporary 29 
14 
 
hypocalcemia accounted for the majority of overall morbidity in patients undergoing pCND, 1 
when temporary hypocalcemia was excluded from overall morbidity, it became similar between 2 
the two groups. Although our meta-analysis would suggest that those who undergo TT+pCND 3 
may have a 35% reduction in risk of LRR than those who undergo TT alone in the short term (<5 4 
years), it remains unclear how much of this risk reduction is related to increased use of RAI 5 
ablation and potential selection bias in some of the studies examined. 6 
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Table 1. Articles which were excluded after reviewing the full-length text 
First 
Author 
Journal Year, 
Country 
Title Main reason(s) for excluding 
from analysis 
Henry (32) Langenbeck’s 
Archives of Surgery 
1998, 
France 
Morbidity of prophylactic lymph node 
dissection in the central neck area in patients 
with papillary thyroid carcinoma. 
The TT alone group had 
patients with benign thyroid 
disease. 
Steinmuller 
(33) 
Langenbeck’s 
Archives of Surgery 
1999, 
Germany 
Complications associated with different 
surgical approaches to differentiated thyroid 
carcinoma. 
Unable to separate some 
patients with follicular thyroid 
carcinoma and some who had 
therapeutic LND. 
Wada (34) Annals of Surgery 2003, Japan Lymph node metastasis from 259 papillary 
thyroid microcarcinomas: frequency, pattern 
of occurrence and recurrence, and optimal 
strategy for neck dissection. 
Unable to separate some 
patients who underwent 
therapeutic CND. 
Gemsenjager 
(35) 
Journal of the 
American College of 
Surgeons 
2003, 
Switzerland 
Lymph node surgery in papillary thyroid 
carcinoma. 
Unable to separate patients with 
therapeutic LND and 
lobectomy. 
Sywak (8) Surgery 2006, 
Australia 
Routine ipsilateral level VI lymphadenectomy 
reduces postoperative thyroglobulin levels in 
papillary thyroid cancer.  
Data from this study were 
included into a later study (25).  
Palestini 
(36) 
Langenbeck’s 
Archives of Surgery 
2008, Italy Is central neck dissection a safe procedure in 
the treatment of papillary thyroid cancer? Our 
experience. 
Unable to exclude some 
patients with cN1. Also no 
follow-up and recurrence data 
were available. 
Davidson Laryngoscope 2008, USA Papillary thyroid cancer: Controversies in the Unable to separate patients who 
had nodal plucking, therapeutic 
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(37) management of neck metastasis. CND, LND or combination 
Hu (38) Chinese Journal of 
Cancer 
2008, China Application of central lymph node dissection 
to surgical operation for clinical stage N0 
papillary thyroid carcinoma. 
No follow-up or recurrence 
data were reported. 
Sadowski 
(39) 
Surgery 2009, USA Routine bilateral central lymph node clearance 
for papillary thyroid cancer. 
All patients who underwent 
CND had cN1. 
Besic (40) Annals of Surgical 
Oncology 
2009, 
Slovenia 
Extent of thyroidectomy and 
lymphadenectomy in 254 patients with 
papillary thyroid microcarcinoma: a single 
institution experience 
Too few (i.e. <10) patients in 
the prophylactic arm. 
Rosenbaum 
(41) 
Archives of 
Otorhinolaryngology 
Head Neck Surgery 
2009, USA Central neck dissection for papillary thyroid 
cancer. 
Unable to exclude patients with 
cN1. 
Giles (42) Surgery 2009, 
Turkey 
The long term outcome of papillary thyroid 
carcinoma patients without primary central 
lymph node dissection: Expected improvement 
of routine dissection. 
Only included patients who 
underwent TT without CND. 
Bonnet (43) Journal of Clinical 
and Endocrinology 
Metabolism 
2009, 
France 
Prophylactic lymph node dissection for 
papillary thyroid cancer less than 2cm: 
Implications for radioiodine treatment. 
Prophylactic LND were 
included. Also no TT alone 
group was available for 
comparison. 
Lim (44) British Journal of  
Surgery 
2009, Korea Central lymph node metastases in unilateral 
papillary thyroid microcarcinoma. 
No TT alone group was 
available for comparison. 
Shen (45) Surgery 2010, USA Central neck lymph node dissection for 
papillary thyroid cancer: The reliability of 
surgeon judgment in predicting which patients 
All patients had therapeutic 
CND. 
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will benefit 
Chung (46) Journal of the 
Korean Surgical 
Society 
2010, Korea Is central lymph node dissection mandatory in 
2 cm or less sized papillary thyroid cancer? 
All patients had lobectomy. 
Shindo (47) Archives of 
Otorhinolaryngology 
Head Neck Surgery 
2010, USA  
 
Total thyroidectomy with and without 
selective central compartment dissection 
The TT alone group had benign 
thyroid disease. 
Bozec (48) European Archives 
of 
Otorhinolaryngology 
2011, 
France 
Clinical impact of cervical lymph node 
involvement and central neck dissection in 
patients with papillary thyroid carcinoma: a 
retrospective analysis of 368 cases 
TT alone group was not 
available. Also some patients 
had therapeutic CND or LND. 
Forest (49) Annals of Surgery 2011, 
Australia 
Central compartment dissection in thyroid 
papillary carcinoma 
No TT alone group was 
available for comparison. 
Mitra (50) Journal of 
Laryngology & 
Otology 
2011, UK Effect of central compartment neck dissection 
on hypocalcaemia incidence after total 
thyroidectomy for carcinoma. 
No follow-up or recurrence 
data reported. 
Teixeira (6) Surgery 2011, Brazil The incidence of central neck micrometastatic 
disease in patients with papillary thyroid 
cancer staged preoperatively and 
intraoperatively as N0 
No TT alone group for 
comparison. 
Kutler (51) Head and Neck 2012, USA Routine central compartment lymph node 
dissection for patients with papillary thyroid 
carcinoma. 
Unable to exclude patients who 
had hemithyroidectomy and 
CND. Also some therapeutic 
LND were included. 
Hyun (52) Annals of Surgical 2012, Korea Impact of combined prophylactic unilateral 
central neck dissection and 
All patients underwent 
26 
 
Oncology hemithyroidectomy in patients with papillary 
thyroid microcarcinoma 
hemithyroidectomy. 
Zhang (53) Journal of Clinical 
Endocrinology and 
metabolism 
2012, China Risk factors for neck nodal metastasis in 
papillary thyroid microcarcinoma: a study of 
1066 patients 
All patients underwent 
hemithyroidectomy. 
Hartl (54) Annals of Surgery 2012, 
France 
Optimization of staging of the neck with 
prophylactic central and lateral neck dissection 
for papillary thyroid carcinoma 
All patients routinely 
underwent prophylactic CND 
and ipsilateral LND. 
Yoo (55) World Journal of 
Surgery 
2012, USA Level VI lymph node dissection does not 
decrease radioiodine uptake in patients 
undergoing radioiodine ablation for 
differentiated thyroid cancer 
Unable to separate some 
patients who underwent 
therapeutic CND 
Giordano 
(56) 
Thyroid 2012, Italy Complications of central neck dissection in 
patents with papillary thyroid carcinoma: 
results of a study on 1087 patients and review 
of the literature 
No follow-up or recurrence 
data reported. 
Abbreviations: TT = total thyroidectomy; cN1 = clinically involved lymph node metastases; LND = lateral neck dissection; CND = 
central neck dissection
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Table 2. A summary and comparison of baseline characteristics between total thyroidectomy + prophylactic central neck dissection 
(group A) and total thyroidectomy alone (group B) 
First  
Author 
(Country) 
No. of 
patients 
Mean 
Age at 
operation 
(years) 
Sex ratio 
(Male: 
Female) 
Mean 
tumor 
size 
(mm)  
ETE 
(%) 
Multifocality 
(%) 
No 
significant 
difference 
between A 
and B 
No. of 
central LNs 
excised* 
Incidence of 
central LNM 
(%) 
A B A B A B 
Roh 
(Korea) 
(17) 
40 73 A=na 
B=48.5 
A=na 
B=9:64 
A=na 
B=22 
A=na 
B=30.1 
A=na 
B=15.1 
1,2,3,4,5 5.6 na 62.2 na 
Choi 
(Korea) 
(18) 
48 53 A=52 
B=48 
A=6:42 
B=11:42 
A=6.8 
B=7.3 
A=45.8 
B=58.5 
A=31.3 
B=22.6 
1,2,3,4,5 na na 37.5 na 
Bardet 
(France) 
(19) 
36 161 na na na na na na na na 23.5 na 
Perrino 
(Italy) (20) 
92 159 na na na na na na na na 33 – 
52 
na 
Costa 
(Italy) (21) 
126 118 A=46 
B=52 
A=26:100 
B=24:94 
A=17 
B=15 
na A=45.2 
B=40.7 
2,4,5 na na 46.8 5.1 
Zuniga 
(Columbia) 
(22) 
136 130 A=42.9 
B=41.5 
A=10:126 
B=13:117 
na A=44.8 
B=27.3 
A=38.2 
B=13.1 
1,2,3 na na 82.4 na 
Moo 45 36 A=45.7 A=10:35 A=14 A=24.4 A=55.6 1,2,4,5 8.8 1.7 33.3 na 
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(USA) (23) B=49.2 B=4:32 B=20 B=36.1 B=63.9 
Hughes 
(USA) (24) 
78 65 A=46.8 
B=41.2 
A=17:61 
B=16:49 
A=19 
B=20 
A=41.0 
B=16.9 
A=33.3 
B=33.8 
1,2,3,5 6.0 0.0 61.5 9.2 
Popadich 
(Australia, 
USA & 
UK) (25) 
259 347 A=44 
B=48 
A=52:207 
B=81:266 
A=23 
B=22 
A=27.8 
B=24.2 
A=48.3 
B=42.7 
2,3,4,5 6.8 0.35 49.0 0.9 
So (Korea) 
(26) 
119 113 A=49.2 
B=49.8 
A=21:98 
B=16:97 
A=6.6 
B=6.2 
A=51.3 
B=51.3 
A=37.8 
B=23.9 
1,2,3,4 na na 37.0 na 
Lang 
(China) (7) 
82 103 A=52.0 
B=50.0 
A=18:64 
B=22:81 
A=15 
B=10 
A=26.8 
B=14.6 
A=36.6 
B=27.2 
1,2,5 5 0 54.9 4.9 
Wang 
(USA) (27) 
49 37 na na s na na na 9 na 40.8 na 
Raffaelli 
(Italy) (28) 
124 62 A=42.7 
B=43.2 
A=24:100 
B=13:49 
A=12.9 
B=12.1 
na A=51.6 
B=46.8 
1,2,3,5 9.6 1.5 35.5 9.7 
Barczynski 
(Poland) 
(29) 
358 282 na A=75:283 
B=60:222 
na A=13.1 
B=12.8 
A=37.7 
B=35.1 
1,2,4,5 6.7 na na na 
Matching: 1 = age; 2 = sex ratio; 3 = tumor size; 4 = extrathyroidal extension; 5 = tumor multifocality 
Abbreviations: s = significantly different (p-value < 0.05) between group A and B; ns = not significantly different between group A 
and B; na = not available or specified; LN = lymph node; LNM = lymph node metastasis; ETE = extrathyroidal extension 
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Table 3. A comparison of surgical outcomes between total thyroidectomy + prophylactic central neck dissection (group A) and total 
thyroidectomy alone (group B) 
First 
author 
(years) 
No. of 
postoperative 
RAI ablation 
(%) 
No. of postoperative 
hypocalcemia (%) 
No. of recurrent 
laryngeal nerve injury 
(%) 
No. of 
hematoma 
formation 
(%) 
No. of 
wound 
infection / 
seroma (%)  
Total  
morbidity# 
(%) 
Temporary Permanent Temporary Permanent 
Roh (2007) 
(17) 
na A=13 (32.5) 
B=7 (9.6) 
na A=0 (0.0) 
B=3 (4.1) 
A=0 (0.0) 
B=2 (2.7) 
A=1 (2.5) 
B=1 (1.4) 
A=0 (0.0) 
B=0 (0.0) 
A=14 (35.0) 
B=13 (17.8) 
Choi 
(2008) (18) 
A=48 (100) 
B=53 (100) 
A=8 (16.7) 
B=6 (11.3) 
A=0 (0.0) 
B=1 (1.9) 
A=1 (2.1) 
B=0 (0.0) 
na A=0 (0.0) 
B=0 (0.0) 
A=0 (0.0) 
B=0 (0.0) 
A=9 (18.8) 
B=7 (13.2) 
Bardet 
(2008) (19) 
na na na na na na na - 
Perrino 
(2009) (20) 
na A=8 (8.7) 
B=11 (6.9) 
A=3 (3.2) 
B=2 (1.3) 
A=3 (3.3) 
B=5 (3.1) 
A= 1 (1.1) 
B= 4 (2.5) 
A=0 (0.0) 
B=0 (0.0) 
A=0 (0.0) 
B=1 (0.6) 
A=15 (16.3) 
B=23 (14.5) 
Costa 
(2009) (21) 
A=87 (69.0) 
B=62 (52.5) 
na na na na na na - 
Zuniga 
(2009) (22) 
A=79 (58.1) 
B=55 (42.3) 
na na na na na na - 
Moo 
(2010) (23) 
A=31 (68.9) A=14 (31.1) A=0 (0.0) A=2 (4.4) A=0 (0.0) na na A=16 (35.6) 
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B=26 (72.2) B=2 (5.6) B=2 (5.6) B=0 (0.0) B=0 (0.0) B=4 (11.1) 
Hughes 
(2010) (24) 
A=72 (92.3) 
B=56 (86.2) 
A=21 (26.9) 
B=5 (7.7) 
A=2 (2.6) 
B= 0 (0.0) 
A=0 (0.0) 
B=2 (3.1) 
A=0 (0.0) 
B=na 
A=1 (1.3) 
B=2 (3.1) 
A=0 (0.0) 
B=1 (1.5) 
A=24 (30.8) 
B=10 (15.4) 
Popadich 
(2011) (25) 
na A=25 (9.7) 
B=14 (4.0) 
A=2 (0.8) 
B=2 (0.6) 
A=1 (0.4) 
B=8 (2.3) 
A=1 (0.4) 
B=6 (1.7) 
A=5 (1.9) 
B=3 (0.9) 
A=3 (1.2) 
B=5 (1.4) 
A=37 (14.3) 
B=38 (11.0) 
So (2012) 
(26) 
A=101 (84.9) 
B=92 (81.4) 
A=49 (41.2) 
B=38 (33.6) 
A=7 (5.9) 
B=2 (1.8) 
A=4 (3.4) 
B=4 (3.5) 
A=1 (0.8) 
B=2 (1.8) 
A=1 (0.8) 
B=0 (0.0) 
A=0 (0.0) 
B=0 (0.0) 
A=64 (53.8)* 
B=46 (40.7) 
Lang 
(2012) (7) 
A=62 (75.6) 
B=63 (61.2) 
A=15 (18.3) 
B=9 (8.7) 
A=2 (2.4) 
B=1 (1.2) 
A=3 (3.7) 
B=0 (0.0) 
A=1 (1.2) 
B=1 (1.0) 
A=0 (0.0) 
B=1 (1.0) 
A=0 (0.0) 
B=0 (0.0) 
A=21 (25.6) 
B=12 (11.7) 
Wang 
(2012) (27) 
A=35 (71.4) 
B=12 (32.4) 
A=21 (42.9) 
B=4 (10.8) 
A=0 (0.0) 
B=3 (8.3) 
A=1 (2.0) 
B=1 (2.7) 
na na na A=22 (44.9) 
B=8 (21.6) 
Raffaelli 
(Italy) (28) 
na A=53 (42.7) 
B=11 (17.7) 
A=1 (0.8) 
B=0 (0.0) 
A=1 (0.8) 
B=0 (0.0) 
A=1 (0.8) 
B=0 (0.0) 
A=0 (0.0) 
B=0 (0.0) 
A=0 (0.0) 
B=0 (0.0) 
A=56 (45.2) 
B=11 (17.7) 
Barczynski 
(Poland) 
(29) 
A=231 (64.5) 
B=79 (28.0) 
A=109 (30.4) 
B=37 (13.1) 
A=8 (2.2) 
B=2 (0.7) 
A=26 (7.3) 
B=18 (6.4) 
A=9 (2.5) 
B=6 (2.1) 
na na A=152 (42.5) 
B=63 (22.3) 
Abbreviations: na = not available or reported; RAI = radioactive iodine 
#the sum of all complications; same patient with ≥2 complications was counted as one 
*including 2 chyle leaks 
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Table 4. A comparison of locoregional recurrence rate between total thyroidectomy + prophylactic central neck dissection (group A) 
and total thyroidectomy alone (group B) 
First author 
(year) 
Number of LRR (%) Mean follow-up (months) Number of person-years Incidence rate ratio (95% 
confidence interval) 
A B A B A B 
Roh (2007) (17) 0 (0.0) 3 (4.1) 51 53 170 322 0.27 (0.01 – 5.25) 
Choi (2008) (18) 1 (2.1) 2 (3.8) 24.4 24.4 98 108 0.55 (0.05 – 6.09) 
Bardet (2008) 
(19) 
4 (11.1) 6 (3.7) na* na* - - - 
Perrino (2009) 
(20) 
5 (5.4) 22 (13.8) 69.2 69.2 531 917 0.39 (0.15 – 1.04) 
Costa (2009) 
(21) 
8 (6.3) 9 (7.6) 47 62 494 629 1.13 (0.44 – 2.94) 
Zuniga (2009) 
(22) 
19 (14.0) 26 (20.0) 73.44 95.52 832 1035 0.91 (0.50 – 1.64) 
Moo (2010) (23) 2 (4.4) 6 (16.7) 37.2 37.2 140 112 0.27 (0.05 – 1.32) 
Hughes (2010) 
(24) 
2 (2.6) 2 (3.1) 19.1 27.5 124 149 1.20 (0.17 – 8.52) 
Popadich (2011) 
(25) 
13 (5.0) 29 (8.4) 32 50 691 1446 0.94 (0.49 – 1.81) 
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So (2012) (26) 2 (1.7) 4 (3.5) 44.7 45.4 443 428 0.48 (0.09 – 2.63) 
Lang (2012) (7) 3 (3.7) 3 (2.9) 28.2 31.9 193 274 1.42 (0.29 – 7.04) 
Wang (2012) 
(27) 
0 (0.0) 0 (0.0) 10 10 41 31 0.76 (0.01 – 38.06) 
Raffaelli (Italy) 
(28) 
1 (0.8) 0 (0.0) 25.0 25.5 258 132 1.53 (0.06 – 37.56) 
Barczynski 
(Poland) (29) 
15 (5.8) 37 (13.1) 126.4 128.8 3771 3027 0.33 (0.18 – 0.59) 
Overall 75 149 45.2 50.8 598.9 662.3 0.65 (0.18 – 0.86) 
Abbreviations: LRR = locoregional recurrence; na = not available or reported 
*only medians were provided and therefore IRR could not be calculated
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LEGENDS
 
 
Figure 1. A flow diagram for study selection 
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Figure 2. A forest plot for temporary hypocalcemia 
 
 
Figure 3. A forest plot for overall morbidity 
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Figure 4. A forest plot for overall morbidity after excluding temporary hypocalcemia 
 
 
 
Figure 5. A forest plot for locoregional recurrence (LRR) 
